Cargando…
CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV
Re-directing T cells via chimeric antigen receptors (CARs) was first tested in HIV-infected individuals with limited success, but these pioneering studies laid the groundwork for the clinically successful CD19 CARs that were recently FDA approved. Now there is great interest in revisiting the concep...
Autores principales: | Kim, Gloria B., Hege, Kristen, Riley, James L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6776630/ https://www.ncbi.nlm.nih.gov/pubmed/31611880 http://dx.doi.org/10.3389/fimmu.2019.02310 |
Ejemplares similares
-
Advances in Developing CAR T-Cell Therapy for HIV Cure
por: Qi, Jinxin, et al.
Publicado: (2020) -
CAR-T Cell Performance: How to Improve Their Persistence?
por: López-Cantillo, Gina, et al.
Publicado: (2022) -
How can Cytokine-induced killer cells overcome CAR-T cell limits
por: Cappuzzello, Elisa, et al.
Publicado: (2023) -
CAR-T Cell Therapy for HIV Cure
por: Salgado, Maria
Publicado: (2023) -
Seatbelts in CAR therapy: How Safe Are CARS?
por: Minagawa, Kentaro, et al.
Publicado: (2015)